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Abstract
Industry experience suggests that g-forces sustained when vials containing protein formulations 
are accidentally dropped can cause aggregation and particle formation. To study this phenomenon, 
a shock tower was used to apply controlled g-forces to glass vials containing formulations of two 
monoclonal antibodies and recombinant human growth hormone (rhGH). High-speed video 
analysis showed cavitation bubbles forming within 30 μs and subsequently collapsing in the 
formulations. As a result of echoing shock waves, bubbles collapsed and reappeared periodically 
over a millisecond timecourse. Fluid mechanics simulations showed low-pressure regions within 
the fluid where cavitation would be favored. A hydroxyphenylfluorescein assay determined that 
cavitation produced hydroxyl radicals. When mechanical shock was applied to vials containing 
protein formulations, gelatinous particles appeared on the vial walls. Size exclusion 
chromatographic analysis of the formulations after shock did not detect changes in monomer or 
soluble aggregate concentrations. However, subvisible particle counts determined by microflow 
image analysis increased. The mass of protein attached to the vial walls increased with increasing 
drop height. Both protein in bulk solution and protein that became attached to the vial walls after 
shock were analyzed by mass spectrometry. rhGH recovered from the vial walls in some samples 
revealed oxidation of Met and/or Trp residues.
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To ensure drug product quality, it is important to retain the chemical and conformational 
purity of proteins during storage, shipping and delivery to patients. Of the many chemical 
degradation paths and physical instabilities to which proteins may be subjected, aggregation 
is one of the most prevalent1. The presence of aggregated proteins in certain cases has been 
associated with reduced efficacy, induction of unwanted immune responses, and 
anaphylactic shock2,3.
One largely unrecognized cause of protein damage is mechanical shock to the primary drug 
product container. Vials and syringes that are dropped by patients or caregivers may 
experience severe mechanical shock, but unless the container shatters, the contents are 
typically administered without further examination. When dropped primary containers hit a 
solid surface, the solutions inside experience mechanical shock, and the resulting shock 
waves and associated fluid mechanics may cause cavitation. Cavitation is the formation, 
growth, and collapse of cavities in a liquid4–6. Cavities formed by mechanical forces 
imposed by the high g-forces that arise from the mechanical shock of dropping are unstable, 
and rapidly implode. When the cavities violently collapse, hot spots are created4–8. These 
extremely short-lived and localized hot spots are local regions of extremely high 
temperatures and pressure that may reach thousands of Kelvin and hundreds of atmospheres, 
respectively4–8. During the collapse of a cavity, hydrogen and hydroxyl radicals can also be 
formed4,9–11.
As a result of the high temperatures, high pressures and free radical formation that occur 
during cavitation, protein molecules can be damaged10. For example, cavitation resulting 
from therapeutic ultrasound has been shown to cause structural changes in several different 
proteins including cytochrome c, lysozyme, bovine serum albumin, trypsinogen, RNAse and 
α-chymotrypsinogen12, 1314. Furthermore, hydroxyl radicals produced during cavitation 
have been shown to crosslink proteins and cause formation of protein particles15,16.
There have been observations of shipping- and handling-induced aggregation and particle 
formation in formulations therapeutic proteins contained in their final drug product vials and 
prefilled syringes17,18. Furthermore, we hypothesize that if a patient or caregiver were to 
drop a vial onto a hard surface, undetected cavitation could occur, fostering formation of 
protein aggregates and proteinaceous particles. To simulate shock that could occur as a 
result of shipping and/or accidental dropping, a mechanical drop tester was used to apply 
controlled mechanical shock to glass vials containing formulations of two different 
monoclonal antibodies or recombinant human growth hormone. High speed video 
photography was used to record the formation and collapse of cavitation bubbles and fluid 
flows over sub-millisecond timescales. The formation of free radicals that formed during 
cavitation was confirmed by fluorescence spectroscopy using a hydroxyphenylfluorescein 
assay. Damage to the proteins was quantified by measuring aggregate levels with size 
exclusion chromatography, and subvisible particle counts made by microflow imaging. The 
protein adhering to the vial walls following shock treatment was also quantified. Chemical 
degradation of the proteins was assessed by high performance liquid chromatography and 
mass spectrometry.
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Two model proteins were used for the majority of the studies: antistreptavidin IgG1 
(provided by Amgen, Inc.) and recombinant human growth hormone (rhGH). 
Antistreptavidin was formulated at either 1 mg/mL or 35 mg/mL in 20 mM histidine buffer, 
pH 6. Recombinant human growth hormone (rhGH) was purified from inclusion bodies 
produced in E. coli19 and formulated at 1.75 mg/mL in 2 mM sodium phosphate, pH 7.4. In 
a limited study to confirm video results, formulations containing a second monoclonal 
antibody (mAb1) at a concentration of 1 mg/mL in a 20mM histidine buffer, pH 6 were also 
examined.
Sample Preparation and Mechanical Shock Treatment
Protein formulations were filtered with a 0.2 um syringe filter prior to shock treatment. 4 mL 
sterilized borosilicate glass vials (West Pharmaceuticals, Lionville, PA) were rinsed with 
filtered water, filled with 1 or 4 mL of protein formulation and sealed at ambient pressure 
with chlorobutyl stoppers (West Pharmaceuticals, Lionville, PA) that had been rinsed with 
filtered water. To simulate the high g-forces and mechanical shock that may be sustained 
when a drug vial is dropped, a Lansmont Model 15D shock test system (Monterey, CA) was 
used. Vials were mounted using a custom-designed holder in an upright position on the 
falling block of the shock test system, and supported by a Teflon® base. Sample vials were 
dropped from heights ranging from 10 to 40 inches. Un-dropped samples (referred to as “0 
in”) in identical vials were used as controls.
High Speed Video Analysis
In initial experiments, a Keyence (Osaka, Japan) VW-9000 high speed microscope was used 
to record images at a rate of 6000 frames per second of the vials as they underwent 
mechanical shock. In additional studies, a Phantom high-speed camera was used to record 
images at a rate of 66,666 frames per second during mechanical shock as vials containing 
either 1 or 3 mL of mAb1 formulation were dropped in the Lansmont shock test system.
Using the Phantom high speed camera, high speed images also were recorded of vials that 
were dropped by hand and contacted a hard surface after a free-fall of approximately 1 m. 
These vials struck the surface at various angles.
Hydroxyphenyl Fluorescein Assay to Detect Cavitation-Induced Free Radicals
In the presence of free radicals, hydroxyphenyl fluorescein forms the highly fluorescent 
product fluorescein. Hydroxyphenyl fluorescein (Invitrogen, Carlsbad, CA) was added to the 
1 mg/mL protein solutions to a concentration of 5 μM, and 1mL of the resulting solution 
filled into 4 mL vials. Following shock treatment, the samples were placed in a fluorometer 
(SLM 8000, SLM, Urbana, IL) After excitation at 490 nm, fluorescence emission intensity 
of the samples was measured at 515 nm. A fluorescein standard curve was used to determine 
the concentration of fluorescein in the samples.
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Size Exclusion Chromatographic Analysis of Soluble Aggregates and Monomeric Protein
Samples were analyzed using size exclusion chromatography to determine the amount of 
monomeric protein and soluble aggregates before and after mechanical shock treatment. 
Prior to analysis, samples were centrifuged for 10 minutes at 9,300g to pellet any insoluble 
material. Size exclusion chromatography was carried out using a Beckman HPLC system 
(Beckman Coulter Inc, Fullerton, CA). For analysis of antistreptavidin samples, the mobile 
phase was 100 mM sodium phosphate, 300 mM sodium chloride, 0.01% sodium azide, pH 
7, and a flowrate of 0.6 mL/min was used. For analysis of rhGH samples, the mobile phase 
consisted of 25 mM ammonium bicarbonate, 0.01% sodium azide, pH 7.4, and 1 mL/min 
flowrate was used. For both of the proteins, 100 μL injections on a TSK-GEL G3000SWXL 
column with an SW guard column were used. Absorbance at 280 nm was measured.
Microflow Imaging Analysis of Sub-visible Particulates
A benchtop FlowCAM (Fluid Imaging Technologies, Yarmouth, ME) was used to image 
and count particles of sizes greater than or equal to 2 μm. A 10x objective and 100 μM 
flowcell were used to analyze 215 μL of sample per assay. Between samples, the flowcell 
was flushed with water that had been filtered through a 0.2 μm filter.
Recovery and Quantification of Protein Adhered to Vial Wall after Cavitation
Two methods were used to recover protein that had adhered to vial walls. The first method 
used urea to dissolve protein from the vial walls. Following shock treatment, all liquid was 
removed from the vials with a pipette. The vials were rinsed twice with 1 mL formulation 
buffer to remove un-adhered protein, and 250 μL of 8 M urea was added to the vials. The 
samples were then incubated overnight at room temperature with mixing on a rotator such 
that the urea solution contacted the entire vial wall surface. The next day, the urea solution 
was diluted 4x in order to be compatible with a standard Bradford total protein assay. 
Bradford reagent and the diluted urea solutions were mixed in a 1:1 ratio, incubated at room 
temperature for 5 minutes, and the absorbance at 595 nm was measured and compared to 
that for a placebo blank. A standard curve using the same protein and buffer as that in the 
mechanically-shocked samples was used.
A second method used guanidine hydrochloride solution to remove the protein from the vial 
walls. Following mechanical shock treatment, the solution was removed from the vials with 
a pipette. Residual solution was then removed by rinsing the vials twice with 1 mLbuffer. 
Finally, 0.5 mL of 7.5 M guanidine hydrochloride, 0.25 M tris, pH 7.5 was added to the 
vials and incubated overnight at room temperature mixing on a rotator such that guanidine 
could access all of the vial wall surface. The next day, the absorbance was measured at 280 
nm to determine the amount of protein recovered from the vial walls. Absorbance values 
were corrected by subtracting absorbance values for appropriate buffer blanks.
Tryptic Digestion/HPLC Analysis of Protein Degradation
Samples from the bulk solution and samples recovered from the washed vial walls were 
enzymatically digested following shock treatment using trypsin. For antistreptavidin 
samples, a protocol similar to that developed by Ren, et al.20 was used. All of the bulk 
solution was removed from the vials after shock treatment. The bulk solution was diluted 
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into denaturation buffer (7.5 M guanidine hydrochloride, 0.25 M tris, pH 7.5) to a final 
concentration of 1 mg/mL and a final volume of 500 μL. After the solution was removed 
from the vials, they were rinsed with buffer. 500 μL of denaturation buffer was added to the 
vials and incubated overnight to recover protein from the vial walls. The next day, 3 μL of 
0.5 M DTT were added to all samples and incubated at room temperature for 30 minutes. 
Next, 7 μL of 0.5 M iodoacetic acid was added and incubated in the dark for 15 minutes. 4 
μL of 0.5 M DTT were added to the samples and samples were buffer exchanged into 
digestion buffer (0.1 M tris, pH 7.5) using NAP-5 columns (GE Healthcare, Piscataway, 
NJ). Trypsin was added to the samples in a 1:25 trypsin:antistreptavidin ratio and incubated 
at 37 °C for 30 minutes. The reaction was quenched with 5 μL of 20% formic acid. Reversed 
phase chromatography analysis was conducted using a Phenomenex (Torrance, CA) Jupiter 
C18 column on an Agilent (Palo Alto, CA) 1100 Series system. The flowrate was 0.2 
mL/min and a linear gradient of 0–50% B (Buffer A: 0.1% trifluoroacetic acid, Buffer B: 
90% acetonitrile, 0.085% trifluoroacetic acid) over 195 minutes was used for elution. 
Absorbance at 215 nm was measured.
For rhGH samples, following shock treatment, all bulk solution was removed from vials, 
and the vials were rinsed with buffer. Bulk solution and the vials were frozen separately at 
−80°C and shipped on dry ice to The University of Kansas, where trypsin or chymotrypsin 
digestion and mass spectroscopy analysis were performed on the samples. Samples of the 
bulk solutions that had not been subjected to shock treatment were used as controls. For the 
bulk solution samples, 10 μL of sample was digested with 50 μL of trypsin or chymotrypsin 
solution (20 μg/mL in 0.1 M ammonium bicarbonate, pH 7.8) at 37°C overnight. For 
analysis of protein adhering to vial walls, 50 μL of trypsin solution was added directly to the 
vials and the protein adhering to the vial walls was digested overnight at 37°C. Following 
digestion, LC-MS analysis was run with a Presto-FF-C18 column. A 1 hour gradient from 
10–50% acetonitrile was used followed by a shorter gradient to 80% acetonitrile for 
washing. The chromatographic system used was an Acquity UPLC system (Waters Corp., 
Milford, MA) coupled to a SYNAPT-G2 (Waters Corp., Milford, MA) mass spectrometer. 
The flow rate was 20 μL/min. The SYNAPT-G2 instrument was operated for maximum 
resolution with all lenses optimized on the [M+2H]2+ ion from the [Glu]1-fibrinopeptide B. 
The cone voltage was 45 V and AR was admitted to the collision cell. The spectra were 
acquired using a mass range of 50–2000 amu. The data were accumulated for 0.7 sec per 
cycle. Data were analyzed with the ProteinLynx Global Server from Waters Corp. (Millford, 
MA). Specific oxidation yields were calculated through the integration of peak areas in the 
extracted ion chromatogram of the most abundant ion of the respective tryptic peptide. It 
was assumed that the electrospray-ionized peptides of any oxidative modifications have 
similar mass spectrometric properties as the respective ions of the native peptides due to the 
small mass difference.
Computational Fluid Dynamics Calculations of Mechanical Shock-Induced Cavitation
The transient behavior of fluid within a vial impacting a solid surface was modeled using 
Fluent’s (ANSYS, Inc., Canonsburg, PA) Volume of Fluid (VOF), axisymmetric solver with 
the Reynolds Averaged Navier-Stokes (RANS) turbulence model described by the realizable 
k-ε closure model. A pressure-velocity coupled algorithm was used to calculate the flow 
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field with a 2nd order discretization for the momentum, turbulence, and energy equations. 
Vials were modeled as containing water in the bottom 1/3rd of the vial with air at 1 atm in 
the remaining area with appropriate meniscus height and shape. The wall boundaries were 
modeled with no-slip conditions using standard wall functions to account for the viscous 
boundary layer at the surface of the vial. The temperatures for all the boundary conditions 
were set to 293K. The fluid used in the comparison of simulated results to experimental data 
for model validation was water at standard temperature and pressure. The Ideal Gas Law 
was selected to allow compressible behavior of the gas phase and a user-defined function 
implemented for the compressible behavior of the liquid phase. The compressibility of water 
as a function of pressure was calculated using the bulk modulus of water. A sliding wall 
mesh was utilized to simulate the fall and rebound of the vial.). Initial fluid velocities 
matched the wall’s downward velocity at impact Three impact cases were evaluated to 
simulate dropping a vial of containing water from a height of 90 cm onto “soft” and “hard” 
surfaces: (i) a soft, 5-cm foam-padded surface, yielding an impact of 50g, (ii) a soft, 1-cm 
foam-padded surface, yielding an impact of 500g, and (iii) a hard metal surface, with a 
corresponding impact of 5000g. These gravitation accelerations were estimated from high-
speed images using the vial geometry, recorded vial positions and the video frame rate to 
determine velocities immediately before and after contact. The 90-cm drop heights was 
chosen to correspond drop distances that a vial might experience when falling off a counter 
or out of a user’s hand.
A total of 21,219 quadrilateral elements were used to achieve a high quality computational 
mesh, resulting in an average mesh density of 2,072 per square millimeter. The maximum 
cell skewness was 0.50, and the minimum orthogonal quality of 0.79. The maximum growth 
rate from one element to the next was 10%. Convergence criteria for the computational 
domains were met when the residuals for pressure, momentum, and turbulence were below 
10−3 and below 10−6 for the energy equation.
RESULTS
Indications of Cavitation
High Speed Video Analysis—To visualize fluid motion and cavitation occurring in 
liquids within partially-filled vials during shock treatment, high speed video of 
antistreptavidin formulations in partially-filled vials was captured as the vials were dropped 
in the Lansmont Model 15D shock test system. Figure 1 shows selected time lapse images of 
a representative vial during shock treatment; full video is available in the supplementary 
material. Time 0 represents the time point when the vial hit the bottom platform of the shock 
tower and began to rebound. As the vial began to rebound, the meniscus inverted, and a jet 
of liquid shot up towards the top of the vial. As the jet formed, cavitation bubbles could be 
seen near the bottom of the vial at about 500 μs after impact. The cavitation bubbles quickly 
collapsed within a few hundred microseconds.
Similar cavitation was also observed when mAb1 solutions in the same type of 4mL vials 
were dropped in the Lansmont Model 15D shock test system from a height of 40 inches 
(Figure 2). Cavitation was evident in images recorded after 165 μs. Vials filled with 3 mL of 
mAb1 solution showed more extensive cavitation than vials filled with 1 mL, and the 
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cavitation bubbles that were produced appeared to oscillate in size. After some of the 
bubbles collapsed, new cavitation events rapidly followed, suggesting that shock waves 
emanating from the collapsing primary cavitation sites and/or that echoes of the original 
shock wave caused additional bubble formation. Cavitation was not observed when vials 
were filled with deionized water (Figure 3).
When the orientation of the vial upon contact with a hard surface was varied by hand-
dropping vials containing 1 mg/mL mAb1 solutions and allowing them to free-fall for ~1m, 
cavitation was observed. In these vials, the pattern and position of the cavitation bubbles 
were highly variable, depending on the orientation of the vials at the point of contact with 
the surface. Occasionally, vial breakage was observed as a result of the free-fall drops; no 
attempt was made to recover or analyze samples in vials that broke. A representative 
sequence of high-speed video images for a square impact between the vial and the surface is 
shown in Figure 4, and for an angled impact in Figure 5; full video sequences are provided 
in the supplementary material. In these studies, where images were recorded using the 
Phantom camera at very high speeds, cavitation could be observed within 30 μs after the 
falling vial contacted the hard surface.
Hydroxyphenyl Fluorescein Assay—Because collapse of cavitation bubbles was 
expected to produce free radicals, hydroxyphenyl fluorescein (HPF) was used to detect 
hydroxyl radicals produced during mechanical shock treatment. Upon reacting with a 
hydroxyl radical, HPF is converted to the fluorescent molecule fluorescein21. HPF was 
added to vials prior to mechanical shock treatment and the fluorescence intensity was 
measured after treatment. A fluorescein standard curve was used to determine the 
concentration of fluorescein produced during shock treatment, and the results are shown in 
Figure 6. Between 20 and 40 nM of fluorescein were detected in the vials after shock 
treatment. The quantity of fluorescein that is formed is only a qualitative indicator of the 
formation of free radicals, because the free radicals that are produced during cavitation 
would be expected to react not only with HPF but also with the buffer and protein. Thus, it 
is likely that far more than 20–40 nM of free radicals were formed as a result of shock 
treatment.
Results of Computational Fluid Dynamics Calculations—Numerical simulations of 
the fluid behavior, in particular pressure-field characteristics, were conducted under each of 
the three impact cases (described in the Methods) to assess whether the conditions for 
cavitation would be satisfied and in what regions of the vial such conditions might occur. 
Figure 7 shows the computed pressure fields within the vials. At the bottom of each of the 
vials is a low pressure region, with the magnitude of the low pressure being dependent on 
the drop conditions. Each of the three impact cases has the same maximum pressure in the 
upper portion of the vial, but the low pressure magnitudes are greatly different. The vapor 
pressure of the water in these simulations is 3.5 kPa. Vials dropped on “soft” surfaces, 
which produce shock that might be typical of that experienced by the contents of a vial that 
has been protected by secondary packaging, are higher than 3.5 kPa, whereas vials dropped 
on “hard” surface showed low pressures well below the vapor pressure of water. This 
indicates that only the hard-impact, metal on metal case is likely to cause cavitation.
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Analysis of Bulk Liquid Within Mechanically-Shocked Vials
Following shock treatment, the solution from dropped and control non-dropped vials was 
removed and analyzed for protein aggregates, particles, and protein chemical damage.
Size Exclusion Chromatography—Size exclusion chromatography was used to 
measure the concentrations of monomer and soluble aggregates in the bulk solution 
following shock treatment. For all sample types tested (1.0 mg/mL antistreptavidin, 35 
mg/mL antistreptavidin, and 1.75 mg/mL human growth hormone), no significant loss of 
monomer or increased level of soluble aggregates resulting from application of mechanical 
shock could be detected by size exclusion chromatography (data not shown).
Particle Count and Size Distribution—FlowCAM microflow imaging analysis was 
used to count and size particles of size equal to or greater than 2 μm in 1 mL samples of 
each of three formulations (antistreptavidin at 1 or 35 mg/mL, and rhGH at 1.75 mg/mL) 
following application of mechanical shock to vials (Figures 8a,c,e). Shock treatment resulted 
in an increase in the number of particles. Drop height did not appear to have a large effect on 
the number of particles counted; all drop heights produced about the same number of 
particles for a given protein and protein concentration. For both antistreptavidin and rhGH, a 
large fraction of the particles that formed after application of mechanical shock showed 
long, fibrillar aspect ratios (Figures 8b,d,f).
In a separate experiment to determine the effect of fill volume on particle formation, a set of 
samples was prepared by filling vials with either 1 or 4 mL of a 1.75 mg/mL rhGH 
formulation. These vials were dropped from a height of 40 inches in the Lansmont shock 
tester. In vials filled with 4 mL solution, cavitation was more apparent than in the vials with 
a 1 mL fill volume. The concentrations in the solution of microparticles of size equal to or 
greater than 2 μm were measured before and after shock treatment using the FlowCam 
instrument. Prior to shock testing, an average of 11,100 particles of size equal to or greater 
than 2 μm/mL were detected in the rhGH solutions. After a single drop, the particle 
concentrations increased to 16,800±700 particles/mL in vials filled with 1mL of solution, 
and to 31,300±3,500 particles/mL in vials filled with 4 mL of solution.
Tryptic Digestion/RP-HPLC Analysis of Protein Degradation—Trypsin digestion 
followed by reverse-phase HPLC was used to monitor chemical damage to the protein as a 
result of shock treatment. The bulk solution from 35 mg/mL antistreptavidin samples was 
digested with trypsin and analyzed on reversed phase chromatography. No chemical 
differences in proteins remaining in the bulk solution were detected in the dropped samples 
compared to the control samples (data not shown).
Bulk solution rhGH samples were also digested with trypsin and analyzed by mass 
spectroscopy. Both control samples and samples of bulk solution dropped from a height of 
40 inches showed similar levels of oxidation of methionine-14, methionine-125, 
methionine-170, and tryptophan (about 1% oxidation or less, data not shown).
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Analysis of Protein Recovered from Vial Walls
Following shock treatment, gelatinous specks of protein were easily visible on the vial walls. 
The protein that adhered to the vials walls in the form of these gelatinous globules was 
recovered and quantified and analyzed for chemical damage.
Quantification of Recovered Protein—The protein adhering to the vial walls was 
recovered using guanidine or urea to remove the protein from the vial walls and quantified 
using the absorbance at 280 nm and the Bradford assay, respectively. The amount of protein 
recovered per vial is shown in Figure 9. In all cases, guanidine was more effective at 
removing adherent protein from the vial walls than was urea. Although the efficiency with 
which protein could be recovered from the vial walls was different depending on whether 
guanidine or urea were used, in both cases (and for both proteins tested) the amount of 
protein that adhered to the walls and could be removed for analysis increased as the drop 
height was increased in the mechanical shock tester.
Trypsin Digestion—After recovering the protein with guanidine, trypsin or chymotrypsin 
digestion and reverse-phase chromatography was used to monitor any chemical 
modifications to the protein. Chemical damage as a result of shock treatment was not 
detected for the 35 mg/mL antistreptavidin samples (data not shown).
Following recovery from the vial walls, rhGH samples were digested and analyzed by mass 
spectroscopy with focus on the oxidation of Met and Trp. Five series of samples were 
analyzed after trypsin digestion, where large sample-to-sample variations were recorded. For 
example, series 1 clearly indicated a significant increase of oxidation of Met-14 to Met 
sulfoxide (MetSO) and the single Trp residue compared to controls, while series 2 showed 
only a significant increase of oxidation of Met-170. Series 3 and 4 failed to indicate any 
significant increase of oxidation compared to controls, while series 5 showed an increase in 
Met-14 oxidation only for vials containing 4 mL solution and dropped from 40 inches 
height. Series 5 was also analyzed after chymotrypsin digestion of rhGH, which did not 
show significant oxidation of Met-14 to MetSO. It is possible, that digestion by one enzyme 
vs. another enzyme can bias towards certain products. However, at this point we can only 
conclude that oxidation of Met and Trp may be possible, but cannot be consistently 
observed. This result is consistent with the large sample-to-sample variations in cavitation 
observed by the high speed camera. In this context it is also important to note that hydroxyl 
radicals, generated via cavitation, react rather unselectively with proteins targeting all 20 
amino acids, though with different rate constants22. Upon reaction with Met, hydroxyl 
radicals initially generate sulfide radical cations, which subsequently decompose into α-
(alkylthio)alkyl radicals, whereas MetSO is not a primary product of Met oxidation by 
hydroxyl radicals unless superoxide is generated simultaneously23 It appears that, wherever 
observed, MetSO formation in rhGH may be a consequence of secondary processes, i.e. 
peroxyl radical or peroxide formation.
DISCUSSION
Inadvertent dropping of vials and syringes almost certainly occurs in the clinic and during 
in–home administration of therapeutic protein formulations. Clearly, such events have the 
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potential to cause cavitation, since in the present study, even the relatively minor shock 
incurred when vials dropped only 10 inches onto hard surfaces caused cavitation. In turn, the 
violent collapse of cavitation bubbles and the resulting free radicals, high temperatures, and 
secondary shock waves may be likely to cause localized oxidative and conformational 
damage to proteins.
In the numerical simulations, of the calculated pressure fields within fluids subjected to a 
high acceleration collision (such as that typical of a dropped vial) indicate the generation of 
high-pressure shock waves and associated low-pressure, cavitation-prone regions along the 
bottom surface of the vial. The strength, location and timing of this low pressure region are 
consistent with the high-speed imaging of large vapor bubble formation within a vial under 
similar conditions. The application of energy-absorbing materials such as those that might 
be used in secondary packaging can mitigate this issue, as clearly demonstrated by the two 
soft-impact conditions. Under these conditions, neither a shock wave discontinuity in the 
pressure field nor a pressure region with pressures below the vapor pressure of water is 
observed. Future numerical studies are focusing on understanding the exact roles that 
dynamics (acceleration), vial shape and fluid properties (density, surface tension, viscosity, 
etc.) play in establishing the shock wave and dictating the magnitude of the low-pressure 
region.
In the bulk solution of the vials, there were no detectable changes in monomer or soluble 
aggregate concentrations after the vial contents were subjected to mechanical shock. This is 
not surprising, since the energy released upon collapse of a cavitation bubble is expected to 
be concentrated in an extremely small volume. There were also no visible insoluble 
aggregates formed in the bulk solution following mechanical shock treatment; all of the 
visible aggregates appeared to be attached to the vial walls. However, there was an increase 
in the number of subvisible particles of size greater than or equal to 2 μm detected by 
microflow imaging analysis following shock treatment. The ability of microflow imaging 
techniques to detect protein aggregates at levels below the sensitivity limit for size exclusion 
chromatographic analysis has been documented24. Mechanical shock treatment of samples 
formulated at the higher concentration of antistreptavidin generated more particles than did 
shock treatment of samples formulated at the lower concentration of antistreptavidin (Figure 
8). Again, this might be expected if only protein in a small volume surrounding a collapsing 
cavitation bubble is damaged. Over the range of drop heights tested, the increase in 
subvisible particles in samples subjected to mechanical shock compared to un-dropped 
samples was not dependent on drop height, perhaps suggesting a threshold value of 
mechanical shock is required to create cavitation associated formation of particles.
Joubert, et al., characterized the aggregates of antibodies exposed to various types of 
stress25. Based on size and morphology, the aggregates produced as a result of shock 
treatment most closely resemble the aggregates produced during mechanical stresses such as 
agitation and stirring in their classification scheme. This might indicate that, in addition to 
the effects of cavitation-induced free radicals, the mechanical stresses caused by cavitation 
could also play an important role in generating protein aggregates.
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After shock treatment, protein aggregates adhering to the vial walls were visible. The 
amount of protein recovered from the vial walls increased as drop height increases and was 
concentration dependent. More protein was recovered from the vial walls following shock 
treatment of 35 mg/mL antistreptavidin than was recovered following shock treatment of 1 
mg/mL antistreptavidin. The amount of adherent protein scaled roughly with protein 
concentration. The protein that adhered to the wall of the vial after application of mechanical 
shock was difficult to remove, and resisted rinsing by buffer solutions. We speculate that the 
adherent properties of the gelatinous globules on the walls may have resulted from the 
potential oxidative damage and subsequent chemical crosslinking that resulted from the free 
radicals and high temperatures produced as cavitation bubbles collapsed, or from 
mechanical stresses caused by shock waves associated with collapse of cavitation bubbles.
In vials filled with deionized water with no added protein or buffer, we did not see video 
evidence of cavitation caused by the mechanical shocks that we applied. In previous work, 
we have shown that DNA molecules may serve as nucleation sites for cavitation26. We 
speculate that in the present case, protein molecules may play a similar role. Likewise, 
surfactant micelles, although not examined in this study, might also be able to serve as 
nucleation sites for cavitation.
In all of our studies, the cavitation phenomenon was highly variable from sample to sample. 
High speed video images showed that the number and location of cavitation sites were 
different in every sample tested, perhaps as a result of subtle differences in shape of the 
interior bottom surface of each vial. The sample-to-sample variation was even more 
apparent in the samples that were hand-dropped and thus contacted the surface at a various 
random angles.
The levels and types of chemical damage that were observed in the proteins were also quite 
variable. This variation was consistent not only with the variable cavitation levels that were 
observed by high-speed photography, but also with the inherent difficulties in sampling the 
damaged protein, which had formed small, adherent, gelatinous particles on the vial walls 
that were difficult to rinse off with buffer, instead requiring urea or guanidine HCL to 
remove them.
Chemical changes to antistreptavidin adhering to the vial walls were not detected, but in 
many rhGH samples where cavitation had occurred extensive oxidation was also observed. 
We hypothesize this damage to rhGH is due to the reactive oxygen species such as OH 
radicals produced during cavitation reacting with the protein. A possible explanation for the 
lack of oxidative damage detected in the antistreptavidin sample might be the lack of 
sensitivity of our analytical technique to potential oxidative damage in the relatively large 
mAb molecule, wherein oxidative damage might have been dispersed over a larger number 
of residues. In addition, because our peptide-focused mass spectrometry technique is not 
sensitive to glycan chemical changes, damage would not be detected if the OH radicals 
reacted preferentially with the highly solvent-exposed glycosylated portion of the molecules.
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The mechanical shock caused by dropping unprotected (e.g., not packaged in protective 
secondary packaging) glass vials containing liquid formulations of therapeutic protein from 
heights as low as 10 inches was sufficient to cause cavitation in the liquid, as evidenced high 
speed video and the production of hydroxyl radicals detected by hydroxyphenyl fluorescein. 
Numerical simulations were consistent with high speed video and showed that cavitation 
may be mitigated by energy absorbing materials, such as those often found in secondary 
packaging.
As a result of this cavitation, subvisible particles were created in the bulk solution of the 
vials. In addition, protein particles were visible on the vial walls following shock treatment. 
The amount of protein adhering to the vial walls increased with drop height. For rhGH, the 
protein adhering to the vial walls following shock treatment showed increased levels of 
oxidation.
The loss of monomeric protein due to cavitation likely was not large enough to affect 
potency of protein in the bulk solution. However, the mechanical shock caused subvisible 
particles to form, and such particles have the potential to affect immunogenicity of the 
formulation27. Thus, packaging, formulation excipient composition, and process conditions 
should be designed to minimize mechanical shock and the potential for cavitation.
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Time lapse images of fluid in a partially filled vial as it contacts a solid surface after being 
dropped from a height of 40 inches. In the third frame, recorded 500 microseconds after 
contact, two large cavitation bubbles become visible. These cavitation bubbles collapse 
rapidly, with complete collapse occurring around 1000 microseconds after the initial contact.
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Time lapse images of mAb1 solution in a fully filled vial as it contacts a solid surface after 
being dropped from a height of 40 inches. In the third frame, recorded 330 microseconds 
after contact, many large bubbles appear and grow until they begin to collapse in the seventh 
frame labeled 990 microseconds. These cavitation bubbles collapse rapidly, with complete 
collapse occurring around 1300 microseconds after the initial contact. The Teflon® bumper 
on which the vials were mounted in the mechanical shock tester is visible in the bottom of 
each frame.
Randolph et al. Page 16























Time lapse images of deionized water in a partially filled vial as it contacts a solid surface 
after being dropped from a height of 40 inches. There is no evidence for any bubble 
formation or cavitation in any of the images,
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Time lapse images of a 1 mg/ml mAb formulation in a partially filled vial as it contacts a 
solid surface squarely after being dropped from a height of 1 m without the aid of a shock 
tower. In the third frame, recorded 30 microseconds after contact, many small bubbles 
rapidly appear and disappear in an oscillatory fashion until they completely disappear in the 
ninth frame labeled 120 microseconds.
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Time lapse images of fluid in a partially filled vial containing 1 mg/ml mAb as it contacts a 
solid surface at an angle after being dropped from a height of 1 m without the aid of a shock 
tower. In the second frame, recorded 30 microseconds after contact, many small bubbles 
appear and rapidly disappear, until they almost completely disappear in the ninth frame 
labeled 270 microseconds.
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Concentration of fluorescein liberated from reaction of p-phenylfluorescein with hydroxyl 
radicals generated during shock treatment as a function of drop height. Concentrations were 
determined from the difference in fluorescence between fluid in mechanically-shocked vials 
and fluid in identical, untreated control vials.
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Numerical simulation of 1/3rd filled vial with water being dropped from 90 cm impacting 
under the following conditions: (left) a 2.0″ foam padded impact (50g), (center) a 0.5″ foam 
padded impact (500g), and (right) a metal surface (5000g).
Randolph et al. Page 21























Particle counts and examples of particle morphologies for shock treated 1 mg/mL 
antistreptavidin (A,B), 35 mg/mL antistreptavidin (C,D), and 1.75 mg/mL human growth 
hormone (E,F). The black portion of each bar represents particles with diameters at least 2 
microns and less than 3 microns, the dark grey portion represents particles with diameters at 
least 3 microns and less than 5 microns, the light grey portion represents particles with 
diameters at least 5 microns and less than 10 microns, and the white portion represent 
particles with diameters at least 10 microns. Each bar represents the particle count from one 
vial.
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Amount of protein recovered from the walls of dropped vials following treatment with urea 
(A,C,E) or guanidine hydrochloride (B,D,F). Dropped vials contained 1 mg/mL 
antistreptavidin (A,B), 35 mg/mL antistreptavidin (C,D), or 1.75 mg/mL human growth 
hormone (E,F)
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